Being able to combat the fatigue symptoms common to long COVID would make a life-changing difference for many thousands:
This is one of the first randomized double-blind placebo-controlled trials of a potential long COVID treatment - AXA1125. Randomized control trials are considered to be gold standard for testing potential treatments for an illness.
People living with long COVID in the trial who received AXA1125 had a significant improvement in fatigue compared to those who received a placebo (material matched in appearance and taste to the investigational treatment). The study was double-blind, that is, neither the patients nor the researchers working with the patients knew which patients had the treatment and which patients had a placebo.